[{"id":"39739443-27b5-47de-9366-d6dcb750b600","acronym":"SGNBB228-001","url":"https://clinicaltrials.gov/study/NCT05571839","created_at":"2022-10-07T13:59:56.834Z","updated_at":"2025-02-25T14:09:10.779Z","phase":"Phase 1","brief_title":"A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors","source_id_and_acronym":"NCT05571839 - SGNBB228-001","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PF-08046049"],"overall_status":"Recruiting","enrollment":" Enrollment 275","initiation":"Initiation: 01/03/2023","start_date":" 01/03/2023","primary_txt":" Primary completion: 04/19/2027","primary_completion_date":" 04/19/2027","study_txt":" Completion: 04/18/2028","study_completion_date":" 04/18/2028","last_update_posted":"2025-02-19"}]